After you receive the kit, all the components should be stored in the refrigerator (4-8°C) also up to 1 year. Long term storage, improper storage conditions and large temperature fluctuation cycles may cause precipitates in the TMB solution. These precipitates should not affect the assay noticeably. Nevertheless, if you observe such precipitates, we recommend to avoid them by allowing them to sink to the bottom.
Detection Range
0-25 ng/ml
General Description
Parathyroid Hormone (pTH) (1-34), is a peptide fragment of the naturally occurring human parathyroid hormone and is secreted from cells of the parathyroid glands and finds its major target cells in bone and kidney. It is an important regulator of calcium and phosphorus metabolism, playing a role in calcium homeostasis of bone, kidney, breast, and placenta. pTH (1-34) administration suppresses cardiovascular calcification and down-regulates aortic osteogenic programs driven by diabetes and dyslipidemia. This ELISA was developed with serum from rabbits immunized with pTH (1-34) coupled to a carrier protein. Immunogen: Synthetic peptide: H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Disulfide bond) coupled to carrier protein.
Standard Curve
Citations
Publication ()
Have you cited DEIABL239 in a publication? Let us know and earn a reward for your research.
Pain frequency, severity and QT dispersion in adult patients with sickle cell anemia: correlation with inflammatory markers
Garadah TS , Jaradat AA, AlAlawi ME, Hassan AB , Sequeira RP
Applications: ELISA Reactive species: Human
"Abstract: Background: Inflammatory markers are increased during vaso-occlusive crisis (VOC) in adult patients with sickle cell anemia (SCA), but this is not clear in clinical steady state.
Aim: The present study aims to establish the frequency and intensity of bone pain episodes in adult patients with SCA in clinical steady state and to determine the correlation between different inflammatory markers, other variables including QT dispersion (QTd) and pain frequency and intensity in SCA." Article snippet: Quantification of PTH in serum was performed by enzyme-linked immunosorbent assay (Creative Diagnostics, Shirley, NY, USA).
Figure 1. Demographic data of patients with SCA compared with control.
Background
Parathyroid hormone (pTH (1-34)) is a basic single-chain polypeptide hormone secreted by the chief cells of the parathyroid gland. Parathyroid hormone is composed of 84 amino acids. Its main function is to regulate the metabolism of calcium and phosphorus in vertebrates, causing blood calcium levels to increase and blood phosphorus levels to decrease. The first precursor substance of PTH is first synthesized in the main cell of the parathyroid gland, called preproparathyroid hormone, which contains 115 amino acids. Later, this precursor substance is cleaved in the cell into the second precursor proparathyroid hormone, which contains 90 amino acids. It is then cleaved intracellularly into a polypeptide containing 84 amino acids, namely PTH. The concentration of PTH in normal human plasma is approximately 1 ng/ml.
Figure 1. Parathyroid hormone expression and secretion in parathyroid cells. (Source: Lombardi G, et al., 2020)
The half-life of PTH in circulating blood is approximately 20 minutes, and it is mainly inactivated in the kidneys. Although calcium metabolism in the body is affected by a variety of hormones, the two main hormones that regulate the concentration of calcium ions in the extracellular fluid are PTH and calcitonin secreted by thyroid parafollicular cells. In addition, PTH also indirectly promotes the absorption of Ca2+ in the intestine. The direct effect of PTH on the kidneys is to promote the reabsorption of Ca2+ by the renal tubules, thereby reducing the excretion of Ca2+ in the urine. PTH indirectly increases intestinal absorption of Ca2+ by activating vitamin D3. The secretion of PTH is mainly regulated by plasma Ca2+ concentration. If the secretion of PTH is too strong, the balance between bone formation and bone erosion will be destroyed, and the enhanced osteoclast activity will dominate. In the long run, it will cause the erosion of bone calcium and make it easy to fracture or bone deformity. If the secretion of PTH is insufficient, the excretion of phosphate by the kidneys is reduced, and calcium phosphate is deposited in the bones.
Studies have shown that pTH(1-34) administration inhibits cardiovascular calcification and downregulates the aortic osteogenic program driven by diabetes and dyslipidemia. Therefore, it is necessary to detect the concentration of pTH (1-34) in experimental samples or disease model samples after administration in preclinical studies. Among many tests, the PTH (1-34)-Teriparatide ELISA Kit test is a simple and convenient test tool that can quickly and accurately obtain changes in pTH (1-34).
Alternative Names
Parathormone Parathyrin Parathyroid Hormone
References
1. Wojda SJ, et al., Parathyroid hormone for bone regeneration. J Orthop Res. 2018, 36(10):2586-2594.
2. Arnaud CD Jr, et al., Parathyroid hormone. Annu Rev Physiol. 1967, 29:349-72.
Q: Does this assay detect only Teriparatide (PTH 1-34) and not cross-react with full-length PTH (1-84)?
A: Yes. This product specifically detects Teriparatide (PTH 1-34) and shows no cross-reactivity with full-length PTH (1-84).
Customer Reviews
My Review for PTH (1-34)-Teriparatide ELISA Kit
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Parathyroid hormone and its related peptides in bone metabolism
Parathyroid hormone (PTH) is an 84-amino-acid peptide hormone that is secreted by the parathyroid gland. It has different administration modes in bone tissue through which it promotes bone formation (intermittent administration) and bone resorption (continuous administration) and has great potential for application in sbone defect repair. PTH regulates bone metabolism by binding to PTH1R. PTH plays an osteogenic role by acting directly on mesenchymal stem cells, cells with an osteoblastic lineage, osteocytes, and T cells. It also participates as an osteoclast by indirectly acting on osteoclast precursor cells and osteoclasts and directly acting on T cells. In these cells, PTH activates the Wnt signaling, cAMP/PKA, cAMP/PKC, and RANKL/RANK/OPG pathways and other signaling pathways. Although PTH(1-34), also known as teriparatide, has been used clinically, it still has some disadvantages. Developing improved PTH-related peptides is a potential solution to teriparatide's shortcomings. The action mechanism of these PTH-related peptides is not exactly the same as that of PTH. Thus, the mechanisms of PTH and PTH-related peptides in bone metabolism were reviewed in this paper.
Background: Osteoporosis is a common condition associated with multiple deleterious consequences. No therapy entirely abolishes fracture risk.
Methods: A MEDLINE database (1966 to the present) search was performed for randomized controlled trials in humans using the keywords osteoporosis and parathyroid hormone (PTH) or parathyroid hormone and fracture. The Cochrane database was searched using the search terms osteoporosis and parathyroid hormone.
Results: Parathyroid hormone (usually subcutaneous) dosages varied markedly across the 20 randomized controlled trial studies retrieved. In the range of 50 to 100 micro g/d, effects may be dose-related. Results of larger trials (up to 1637 patients) were conflicting as to whether effects were limited to the spine and suggested detrimental effects on radius bone mineral density. Little data analyzed the effects of PTH in older vs younger subjects or directly compared the effects by sex. Increases in spine bone mineral density are induced by PTH in postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and idiopathic osteoporosis. Parathyroid hormone may protect against gonadotropin-releasing hormone agonist-related bone loss. Effects are less clear at nonspine sites when PTH is used as part of combination or sequential therapies or for treatment of glucocorticoid-induced osteoporosis. Parathyroid hormone decreased the incidence of radiographically detected spinal fractures. The numbers of nonvertebral fractures were too low to be broken down by individual site. Parathyroid hormone injections were difficult for some patients to comply with. Occasionally, PTH-associated hypercalcemia may be dose-dependent, often manifesting early in treatment. An increase in cancer risk from PTH is not reported in humans.
Conclusions: Parathyroid hormone decreases vertebral fractures and increases spinal bone density in postmenopausal osteoporosis and glucocorticoid-induced osteoporosis, but at the expense of a decrease in radius bone density. The long-term safety and nonvertebral fracture efficacy are unknown.
Self-arranged polythiophene on multi-walled carbon nanotube templated composites: Synthesis and application in rechargeable aluminium battery
ELECTROCHIMICA ACTA
Authors: Raju, Vadthya; Rani, J. Vatsala; Basak, Pratyay
This work demonstrates the application of polythiophene/multi-walled carbon nanotube (PTh/MWCNT) composite as electrode material for rechargeable aluminium battery (RAB) consisting Al plate as negative electrode. Chemical in-situ oxidative synthetic procedure was followed for obtaining PTh/MWCNT composite, which defines one-dimensional morphology of as synthesized mixture, deciphered through FESEM and HRTEM analysis. The polymer's successful nanocomposite formation was confirmed through FTIR analysis and EDS elemental mapping. Further application of PTh/MWCNT as cathode against Al anode in 1.5:1 molar ratio of AlCl3:[EMIm]Cl signify the positive electrochemical behaviour. Cyclic voltammetry of the cells show well-defined redox-peaks, demonstrating the possible chloroaluminate ions doping/dedoping at the active electrode. Galvanostatic charge -discharge analysis of the cell yields high specific capacity of similar to 216mAh/g, retaining similar to 100% coulombic efficiency. The cells have shown excellent reversible cycling over different C-rates. XPS analysis of the cycled PTh/MWCNT electrode shows the existence of multi-polaron state associated with S from thiophene of polymer unit affirming the de/-doping chloroaluminate ions occurred. The positive prospect of PTh in its pristine or composite form defines a promising electrode material that deserves intensive study and further development. (C) 2020 Elsevier Ltd. All rights reserved.
Post Traumatic Headache: Clinical care of athletes vs non athletes with Persistent Post Traumatic Headache after Concussion: Sports Neurologist and Headache Specialist Perspective
Purpose The purpose of this paper is to review and outline the similarities and differences in the treatment of athletes compared with that of other populations with a persistent post-traumatic headache after a concussion. Recent Findings After an extensive review of the literature and despite well over 2 million Americans experiencing post-traumatic headache (PTH) each year, a number of which will continue to experience persistent post-traumatic headache (PPTH). There is little evidence on the management of the disorder and essentially no evidence-based research when it comes to the management of athletes. With little evidence available for the treatment of individuals with PPTH, be it athletes or non-athletes, the clinician will need to rely on their experience and the application of existing treatments for migraine and chronic migraine. Clearly, more research is needed, especially with respect to the management of athletes versus non-athletes.
COA
Loading ......
Publication ()
Figure 1. Demographic data of patients with SCA compared with control. 
Figure 1. Parathyroid hormone expression and secretion in parathyroid cells. (Source: Lombardi G, et al., 2020)
